                                                                                                                   
                                                   UNITED STATES                                                   
                                                                                                                   
                                                                                                                   
                                        SECURITIES AND EXCHANGE COMMISSION                                         
                                                                                                                   
                                                                                                                   
                                               WASHINGTON, DC 20549                                                
                                                                                                                   
                                                                                                                   
                                                     FORM 8-K                                                      
                                                                                                                   
                                                  CURRENT REPORT                                                   
                                                                                                                   
                                      Pursuant to Section 13 or 15(d) of The                                       
                                                                                                                   
                                          Securities Exchange Act of 1934                                          
                                                                                                                   
                                 Date of report (Date of earliest event reported):                                 
                                                                                                                   
                                                  April 27, 2023                                                   
                                                                                                                   
                                                 Johnson & Johnson                                                 
                                                                                                                   
                              (Exact name of registrant as specified in its charter)                               
                                                                                                  
  New Jersey                         1-3215                     22-1024240                        
  (State or Other Jurisdiction of    -Commission File Number    -IRS Employer Identification No.  
  Incorporation)                                                                                  
                                                                                                  
                           One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933                            
                                                                                                                   
                                     (Address of Principal Executive Offices)                                      
                                                                                                                   
                                                    (Zip Code)                                                     
                                                                                                                   
                                Registrant's telephone number, including area code:                                
                                                                                                                   
                                                   732- 524-0400                                                   
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
                                                                                                    
  Title of each class               Trading Symbol(s)    Name of each exchange on which registered  
  Common Stock, Par Value $1.00     JNJ                  New York Stock Exchange                    
  0.650% Notes Due May 2024         JNJ24C               New York Stock Exchange                    
  5.50% Notes Due November 2024     JNJ24BP              New York Stock Exchange                    
  1.150% Notes Due November 2028    JNJ28                New York Stock Exchange                    
  1.650% Notes Due May 2035         JNJ35                New York Stock Exchange                    
                                                                                                    
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.

Upon the closing of the initial public offering of Kenvue Inc., Thibaut Mongon will cease to be Executive Vice
President, Worldwide Chairman, Consumer Health and member of the Executive Committee of Johnson & Johnson and will
continue his role as Chief Executive Officer of Kenvue Inc.

Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) T he 2023 Annual Meeting of Shareholders of Johnson & Johnson (the “Company”) was held on April 27, 2023.

(b) At the 2023 Annual Meeting of Shareholders, the shareholders:

• elected all 12 Director nominees named in the 2023 Proxy Statement to the Company ’ s Board of Directors;

• approved, on an advisory basis, the executive compensation philosophy, policies and procedures described in the
“Compensation Discussion and Analysis” section of the 2023 Proxy Statement and the compensation of the Company ’ s
executive officers named in the 2023 Proxy Statement, as disclosed therein;

• approved, on an advisory basis, having an advisory vote on the compensation of the executive officers named in
the Company ’ s proxy statement every one (1) year;

• ratified the appointment of PricewaterhouseCoopers LLP as the Company ’ s independent registered public
accounting firm for the fiscal year 2023;

• did not approve the shareholder proposal for a Vaccine Pricing Report ; and

• did not approve the shareholder proposal for a report on the Impact of Extended Patent Exclusivities on Product
Access.

The following are the final voting results for each of the six items voted on at the meeting.

1. Election of Directors:
                                                                                        
                         Shares For    Shares Against    Shares Abstain      Non-Votes  
  D. Adamczyk         1,786,272,387        16,426,067        16,974,577    353,172,322  
  M. C. Beckerle      1,789,457,274        13,764,941        16,450,816    353,172,322  
  D. S. Davis         1,756,303,275        46,470,790        16,898,966    353,172,322  
  J. A. Doudna        1,789,027,330        14,257,035        16,388,666    353,172,322  
  J. Duato            1,688,009,715       120,870,955        10,792,361    353,172,322  
  M. A. Hewson        1,773,472,628        29,649,436        16,550,967    353,172,322  
  P. A. Johnson       1,804,950,345         9,856,598         4,866,088    353,172,322  
  H. Joly             1,772,344,027        30,395,092        16,933,912    353,172,322  
  M. B. McClellan     1,788,586,733        14,265,282        16,821,016    353,172,322  
  A. M. Mulcahy       1,698,043,017       104,917,215        16,712,799    353,172,322  
  M. A. Weinberger    1,788,359,732        14,280,263        17,033,036    353,172,322  
  N. Y. West          1,793,769,456         9,125,005        16,778,570    353,172,322  
                                                                                        
2. Advisory Vote to Approve Named Executive Officer Compensation:
                                                             
  For                  Against     Abstained      Non-Votes  
  1,685,320,654    123,275,647    11,076,730    353,172,322  
                                                             
3. Advisory Vote on the Frequency of Voting to Approve Named Executive Officer Compensation:
                                                                           
  For 1 Year       For 2 Years    For 3 Years    Abstained      Non-Votes  
  1,785,566,411      4,955,319     22,089,730    7,061,571    353,172,322  
                                                                           
Based on the voting results on this advisory proposal, the Board of Directors has decided that it will include an
advisory vote on executive compensation in the Company’s proxy statement every one (1) year until the next required
advisory vote on the frequency of such votes, which will occur no later than the Company’s Annual Meeting of
Shareholders in 2029.

4. Ratification of Appointment of PricewaterhouseCoopers LLP as the Company’s Independent Registered Public
Accounting Firm for 2023 :
                                                          
  For                  Against    Abstained    Non-Votes  
  2,048,852,179    118,621,657    5,371,517           -0  
                                                          
6. Shareholder Proposal - Vaccine Pricing Report:
                                                             
  For                  Against     Abstained      Non-Votes  
  569,515,836    1,223,800,230    26,356,965    353,172,322  
                                                             
8. Shareholder Proposal - Impact of Extended Patent Exclusivities on Product Access:
                                                             
  For                  Against     Abstained      Non-Votes  
  258,032,003    1,530,773,877    30,867,151    353,172,322  
                                                             
                                                                                                                   
                                                    SIGNATURES                                                     
                                                                                                                   
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
                                                                    
                             Johnson &         (Registrant)         
  Date:    April 28, 2023    Johnson    By:    /s/ Marc Larkins     
 ────────────────────────────────────────────────────────────────── 
                                               Marc Larkins         
                                               Corporate Secretary  
                                                                    
